AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis
Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investors
The collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territory
Alebund holds a substantial non-dilutive equity interest in R1, with the opportunity to participate in future commercial upside through dividends
Shanghai, China – March 17, 2026 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a leading renal-focused biopharmaceutical company, today announced that it has entered into licensing and equity agreements (the “Agreements”) with R1 Therapeutics, Inc. (“R1”). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M. R1 is backed by major global kidney care providers, DaVita, one of the largest kidney care providers globally, and U.S. Renal Care, the largest privately held dialysis provider in the United States and a syndicate of leading global venture capital investors.
Under the Agreements, Alebund has granted R1 an exclusive license to develop, manufacture, and commercialize AP306 outside Greater China (the “R1 Territory”). As part of the transaction, the aggregate financial terms include development, regulatory and commercial milestone payments of up to low triple-digit millions of U.S. dollars, and Alebund will share in the economics of AP306’s success in the R1 Territory through tiered royalty payments in the low double-digit percentage range on net sales. In addition, Alebund holds a substantial non-dilutive equity interest in R1, with the opportunity to participate in future commercial upside through dividends. R1 will fund and lead the global clinical development of AP306, with Alebund as a collaborative development partner, including a global Phase 2b multi-regional clinical trial (“MRCT”) in the U.S. and China planned to initiate later this year. Alebund and R1 will work together to accelerate the global development of AP306.
Gavin Xia, Ph.D., Co-Founder and CEO of Alebund Pharmaceuticals, commented:
“This collaboration validates the global potential of AP306 and represents an important milestone for Alebund. By partnering with R1, global kidney care providers, and financial investors, we can accelerate AP306’s global development. With the support of R1, DaVita and U.S. Renal Care, we are well-positioned to capture the significant market potential in the United States. We look forward to working with the R1 team to bring this potentially transformative therapy to patients worldwide.”
Krishna Polu, M.D., Co-Founder, President and CEO of R1 Therapeutics, commented:
“We are thrilled to launch R1 with the backing of world-class investors who share our conviction in the potential of AP306 to fundamentally change how hyperphosphatemia is managed. AP306 represents a new mechanistic approach – blocking the active transport of phosphorus rather than relying on traditional phosphate binding – and the Phase 2a data published in Kidney International Reports demonstrate compelling efficacy and tolerability. We look forward to advancing the global Phase 2b program in collaboration with Alebund and bringing AP306 to patients around the world.”
About AP306
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis. Unlike conventional phosphate binders, AP306 works by inhibiting the active transport of phosphorus through three key phosphate transporters (NaPi-IIb, PiT-1, and PiT-2) in the gastrointestinal tract, representing a fundamentally new mechanism of action for managing hyperphosphatemia. AP306 was originally discovered by Chugai Pharmaceuticals Co., Ltd. and subsequently licensed to Alebund Pharmaceuticals, which has conducted clinical development of the compound, including a completed Phase 2a study in hemodialysis patients. Results published in Kidney International Reports demonstrated significant reduction in serum phosphate levels with good safety and tolerability. Data from the Phase 2a study has also been presented at the 61st European Renal Association (ERA) Annual Congress.
About R1 Therapeutics
R1 Therapeutics is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease. Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis, a condition associated with serious bone and cardiovascular complications and poorer outcomes when phosphate remains uncontrolled. AP306 is a first-in-class pan-phosphate active transport inhibitor designed to block three key phosphate transporters in the gut, with the potential to deliver rapid and effective phosphate lowering with a significantly reduced treatment burden. R1 has licensed exclusive global rights outside Greater China to AP306 from Alebund Pharmaceuticals and is advancing a global Phase 2b development program. R1 launched with an oversubscribed $77.5 million Series A financing in March 2026 co-led by Abingworth, DaVita Venture Group, and F-Prime, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. For more information, visit www.r1therapeutics.com and follow R1 on LinkedIn.
About Alebund Pharmaceuticals
Alebund Pharmaceuticals is a global leading renal-focused biopharmaceutical company with a vertically integrated platform encompassing R&D, manufacturing, and commercialization. The Company possesses the most comprehensive innovative renal portfolio in terms of indication coverage, with seven drug candidates and one commercialized product (Mircera®) targeting a broad range of renal indications including CKD complications (hyperphosphatemia, renal anemia), IgA nephropathy, diabetic kidney disease, FSGS, and ADPKD. Alebund holds global rights for its core pipeline assets, including AP301 (a best-in-class oral phosphate binder currently in global Phase 3), AP306, AP303 (a first-in-class dual PPAR agonist with FDA Orphan Drug Designation for ADPKD), and AP308 (a first-in-class IgA protease). The Company has completed construction of its manufacturing facility in Yangzhou, China, and has established a dedicated in-house commercialization team in China.
About DaVita
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey-from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of December 31, 2025, DaVita served approximately 295,000 patients at 3,242 outpatient dialysis centers, of which 2,657 centers were located in the United States and 585 centers were located in 14 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
About U.S. Renal Care
U.S. Renal Care, the largest privately held and fastest-growing dialysis provider in the nation, partners with nephrologists to care for more than 37,000 people living with kidney disease across 32 states in the U.S. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence – delivering the best experience and outcomes for its patients. Visit USRenalCare.com to learn more.
礼邦医药宣布与 R1 Therapeutics 达成 AP306 股权及海外授权合作协议
AP306 是一款同类首创（first-in-class）的泛磷酸盐转运蛋白抑制剂，正在开发用于治疗接受透析的慢性肾脏病（CKD）患者的高磷血症
礼邦医药将 AP306 在大中华区以外地区的独家开发、生产及商业化权利授予 R1 Therapeutics——一家由全球领先的肾脏健康服务机构及顶尖生命科学风投基金共同支持的新创公司
本次合作涵盖最高总计过亿美元的里程碑付款，以及基于 AP306 在授权区域净销售额的低双位数百分比阶梯式特许权使用费
礼邦医药作为 R1 的主要股东之一，拥有受反稀释保护的股份，预计通过分红机制共享AP306的商业化回报
中国上海 – 2026 年 3 月 17 日 – 礼邦医药（”礼邦”或”公司”），一家专注于肾脏领域的领先生物制药公司，今日宣布已与 R1 Therapeutics, Inc.（”R1″）签署许可及股权协议（”协议”）。R1 是一家新创的临床阶段生物科技公司，近期完成 7,750 万美元的 A 轮融资并获得超额认购，其背后汇聚了包括 DaVita（全球最大的肾脏健康服务提供商）、U.S. Renal Care（美国最大的私营透析服务商）以及多家全球顶级生命科学风险投资基金的战略支持。
根据协议，礼邦医药已授予 R1 在大中华区以外地区（”授权区域”）独家开发、生产及商业化 AP306 的权利。作为本次交易的一部分，协议项下的整体经济条款包括最高总计过亿美元的开发、注册及商业化里程碑付款；同时，礼邦医药将通过基于净销售额的低双位数百分比阶梯式特许权使用费，分享 AP306 在授权区域取得成功所带来的经济收益。作为战略合作的重要一环，礼邦医药获得 R1 可观的、受反稀释条款保护的股权，这确保了礼邦能通过未来的股息分红，持续且深度地参与 AP306 在全球市场的商业化价值兑现。
R1 将出资并与礼邦共同领导 AP306 的全球临床开发，其中包括一项计划于今年内启动、在美国和中国开展的全球 2b 期多区域临床试验（”MRCT”）。礼邦医药与 R1 将共同加速 AP306 的全球开发。
礼邦医药联合创始人兼首席执行官夏国尧博士表示：
“本次合作不仅是对 AP306 巨大临床潜力的有力印证，更是礼邦全球化战略布局中的关键里程碑。通过与 R1、全球顶尖的肾脏健康服务网络以及医疗健康行业顶级投资者的深度结盟，构建了一个极具执行力的研发网络。在 DaVita、U.S. Renal Care 及相关战略投资人的赋能下，我们已做好充分准备去挖掘并兑现美国市场的庞大商业潜力。我们非常期待与 R1 团队并肩作战，早日将这一具有变革意义的创新疗法带给全球患者。”
R1 Therapeutics 联合创始人、总裁兼首席执行官 Krishna Polu M.D. 表示：
“我们非常荣幸能在肾脏健康领域及医疗健康行业顶级投资者的支持下创立 R1。大家基于一个共同的信念走到了一起：AP306 有望从根本上重塑高磷血症的临床管理模式。作为一款拥有全新作用机制的疗法——通过精准阻断磷的主动转运，而非依赖传统的磷酸盐结合剂—AP306 此前发表于 Kidney International Reports 的 2a 期数据，已展现出令人瞩目的疗效与耐受性。我们期待与礼邦医药紧密合作，全速推进全球 2b 期临床项目，惠及全球肾病患者。”
关于 AP306
AP306 是一款同类首创的泛磷酸盐转运蛋白抑制剂，正在开发用于治疗接受透析的慢性肾脏病（CKD）患者的高磷血症。与传统磷酸盐结合剂不同，AP306 通过抑制胃肠道中三种关键磷酸盐转运蛋白（NaPi-IIb、PiT-1 和 PiT-2）的磷主动转运发挥作用，代表了高磷血症管理的全新理念。AP306 最初由日本中外制药发现，礼邦医药在获取其许可后开展了后续的临床开发工作，包括一项已完成的针对血液透析患者的 2a 期研究。其研究结果发表在 Kidney International Reports 上，并在第 61 届欧洲肾脏协会（ERA）年会上进行了报告。结果显示，AP306 能够显著降低血清磷水平，且具有良好的安全性和耐受性。
关于 R1 Therapeutics
R1 Therapeutics 是一家临床阶段的生物制药公司，专注于开发针对肾脏疾病患者的同类首创疗法。其主要在研项目 AP306 针对接受透析的慢性肾脏病患者的高磷血症——当磷酸盐控制不佳时，该病症与严重的骨骼和心血管并发症及较差的预后密切相关。R1 已从礼邦医药获得 AP306 在大中华区以外地区的全球独家权利，并正在推进全球 2b 期开发项目。R1 于 2026 年 3 月完成超额认购的 7,750 万美元 A 轮融资，由 Abingworth、DaVita Venture Group 和 F-Prime 联合领投，Curie.Bio、SymBiosis 和 U.S. Renal Care 跟投。更多信息请访问 www.r1therapeutics.com，或在 LinkedIn 上关注 R1。
关于礼邦医药
礼邦医药是一家专注于肾脏领域的生物制药公司，拥有涵盖研发、生产和商业化的垂直整合平台。公司拥有全面的创新肾脏管线组合，涵盖七款在研药物和一款已上市产品（Mircera®），覆盖广泛的肾脏适应症，包括 CKD 并发症（高磷血症、肾性贫血）、IgA 肾病、糖尿病肾病、FSGS 和 ADPKD。礼邦医药持有核心管线资产的全球权利，包括 AP301（一款同类最优的口服铁基磷结合剂，目前已完成中国注册性 3 期临床并同步开展全球 3 期临床）、AP306（一款同类首创的泛磷酸盐转运蛋白抑制剂）、AP303（一款同类首创的双重 PPAR 激动剂，已获 FDA 孤儿药资格认定，适应症为 ADPKD）及 AP308（一款同类首创的 IgA 蛋白酶）。公司已在中国扬州建成生产基地，并已在中国组建了专属的商业化团队。
关于 DaVita
DaVita（纽约证券交易所代码：DVA）是一家致力于通过变革医疗服务模式改善全球患者生活质量的医疗健康服务提供商。作为综合肾脏健康服务提供商，DaVita 在临床质量和创新方面已保持行业领先超过 25 年。DaVita 在患者肾脏健康旅程的每一个阶段和场景中提供关护——从延缓肾脏疾病进展到帮助支持肾移植，涵盖居家护理、透析中心、医院及专业护理设施。截至 2025 年 12 月 31 日，DaVita 在 3,242 家门诊透析中心为约 295,000 名患者提供服务，其中 2,657 家中心位于美国，585 家中心分布在全球其他 14 个国家。DaVita 在降低住院率、改善死亡率、促进医疗可及性等方面持续努力，并与肾脏健康行业协作推动全面提升所有患者的护理质量标准。更多信息请访问 DaVita.com/About。
关于 U.S. Renal Care
U.S. Renal Care 是美国最大的私营及增长最快的透析服务提供商，与肾脏病专科医生合作，在全美 32 个州为超过 37,000 名肾脏病患者提供诊疗服务。自 2000 年成立以来，U.S. Renal Care 一直是临床质量、创新和运营卓越的行业标杆，致力于为患者带来最佳的就医体验和健康结果。更多信息请访问 USRenalCare.com。